All systems operational
Q2 2020

Role of dexmedetomidine infusion after coronary artery bypass grafting

Tamer Hamouda · Mohamed Ismail · Tamer Hamed Ibrahim · Hesham Ewila · Ahmed Elmahrouk
10.1186/s43057-019-0014-8 381 Views 3 Citations
3
Citations
381
Views
Abstract

Abstract
Background
Postoperative pain has negative consequences on patients’ outcomes after cardiac surgery. Routine management with opioid and or non-steroidal anti-inflammatory medications has several disadvantages. Dexmedetomidine is a selective α2 agonist used for sedation and analgesia. The use of dexmedetomidine for postoperative pain management and decreasing delirium and agitation in cardiac surgery patients is a matter of debate. Our objective was to determine the role of an early administration of dexmedetomidine in decreasing opioid use post-cardiac surgery and its effects on the quality of postoperative recovery.

Results
Medical records of 120 patients admitted to the cardiac surgery intensive care unit (CSICU) after coronary artery bypass grafting (CABG) in two cardiac centers between December 2015 and December 2016 were reviewed. Patients were divided into two groups. Group A included 55 patients who received dexmedetomidine in a dose of 0.2–0.4 mcg/kg/h on admission to CSICU, and group B included 65 patients who did not receive dexmedetomidine. The primary outcome was the pain score immediately after extubation, and the secondary outcomes included post-extubation sedation and pain scores for 12 h.
There were significant decrease of the pain scores in dexmedetomidine group that continues through the 3rd, 6th, 8th, and 12th hour readings after surgery with mean modified Ramsay scores 0.1 ± 0.0, 0.89 ± 2.05, 0.35 ± 0.1, and 0.12 ± 1.1 respectively compared to 0.46 ± 1.15, 3.46 ± 2.93, 0.98 ± 1.90, and 0.12 ± 1.1 in group B (p < 0.001), significant decrease in cumulative morphine received (p < 0.001, OR = 909, 95% CI 0.05–0.19), favorable reduction in heart rate in dexmedetomidine group (80 ± 1.9 b/min) compared to 96 ± 8.8 b/min in the other group (p = 0.017), and smoother recovery from general anesthesia.

Conclusion
Administration of dexmedetomidine in the early postoperative period can be safe. It may reduce the use of opioids, has sedative, analgesic, and sympatholytic effects that could play a useful role during the management of coronary artery bypass patients, and may improve postoperative recovery.

Cite this Article (APA)
Tamer, H., Mohamed, I., Tamer, H. I., Hesham, E., Ahmed, E. (2020). Role of dexmedetomidine infusion after coronary artery bypass grafting. The Cardiothoracic Surgeon. https://doi.org/10.1186/s43057-019-0014-8
Related Papers
Requirement of artificial intelligence technology awareness for thoracic surgeons
Anshuman Darbari; Krishan Kumar; Shubhankar Darbari; Prashant L. Patil · 2021
26
cites
389
Requirement of artificial intelligence technology awareness for thoracic surgeons
Anshuman Darbari; Krishan Kumar; Shubhankar Darbari; Prashant L. Patil · 2021
26
cites
390
Cardiac myxomas: a review of current treatment approaches and emerging molecular therapies
Patrick Ashinze; Suvam Banerjee; Emmanuel Egbunu; Wuraola Salawu; Abdullaah Idri · 2024
18
cites
389
Cardiac myxomas: a review of current treatment approaches and emerging molecular therapies
Patrick Ashinze; Suvam Banerjee; Emmanuel Egbunu; Wuraola Salawu; Abdullaah Idri · 2024
18
cites
392
Recent advancements in pediatric cardiopulmonary bypass technology for better outcomes of pediatric …
Yasir Saleem; Anshuman Darbari; Rahul Sharma; Amit Vashisth; Anish Gupta · 2022
16
cites
391
Access
View Full Text via DOI
Published in
ISSN 2662-2203
Quartile Q2
AMS Score 72
Field Medicine & Health Sciences
Publisher Springer (Biomed Central Ltd.)
Country 🇪🇬 Egypt
View Journal Profile →
Authors
Publication Details
Year 2020
Language English
Added 24 Aug 2026